New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 8, 2014
07:23 EDTABT, UHS, CYH, ALXN, AUXL, BLUE, OVAS, CAH, BAYRY, ANACDeutsche Bank to hold a conference
39th Annual Healthcare Conference is being held in Boston on May 7-8 with webcasted company presentations to begin on May 8 at 8 am; not all company presentations may be webcasted. Webcast Link
News For OVAS;CYH;ANAC;BLUE;UHS;BAYRY;AUXL;ABT;CAH;ALXN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
January 29, 2015
07:02 EDTCAHCardinal Health raises FY15 non-GAAP EPS to $4.28-$4.38 from $4.10-$4.30
FY15 EPS consensus of $4.26.
07:02 EDTCAHCardinal Health reports Q2 non-GAAP EPS $1.20, consensus $1.10
Subscribe for More Information
06:32 EDTALXNAlexion appoints David Hallal as CEO effective April 1, 2015
Alexion announced that its board has appointed David Hallal as the companyís CEO, effective April 1, 2015. Hallal currently serves as Alexionís COO and is a director of the board. He will succeed Leonard Bell, M.D., Chairman and CEO, who will retire as CEO and continue to serve as Chairman of the Board.
06:28 EDTALXNAlexion sees FY15 non-GAAP EPS $5.60-$5.80, consensus $5.91
Subscribe for More Information
06:26 EDTALXNAlexion plans to focus on serving patients with PNG and aHUS
Subscribe for More Information
06:25 EDTALXNAlexion reports Q4 non-GAAP EPS $1.30, consensus $1.29
Reports Q4 revenue $599.48M, consensus $590.46M
January 28, 2015
15:38 EDTCAH, ABT, ALXNNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Celgene (CELG), consensus 99c... ConocoPhillips (COP), consensus 59c... Abbott Laboratories (ABT), consensus 67c... Occidental Petroleum (OXY), consensus 68c... Colgate-Palmolive (CL), consensus 74c... Ford (F), consensus 23c... Dow Chemical (DOW), consensus 69c... Alibaba (BABA), consensus 75c... Thermo Fisher (TMO), consensus $1.94; Time Warner Cable (TWC), consensus $2.09... Phillips 66 (PSX), consensus $1.34... Alexion Pharmaceuticals (ALXN), consensus $1.29... Baxter International (BAX), consensus $1.31... Cardinal Health (CAH), consensus $1.10... Raytheon (RTN), consensus $1.08... Northrop Grumman (NOC), consensus $2.25... Viacom (VIAB), consensus $1.28... Valero Energy (VLO), consensus $1.32... Sherwin-Williams (SHW), consensus $1.38... Hershey (HSY), consensus $1.06... Mead Johnson (MJN), consensus 88c... Zimmer (ZMH), consensus $1.71... Xcel Energy (XEL), consensus 34c... Royal Caribbean (RCL), consensus 42c... Coach (COH), consensus 66c... Kate Spade (KATE), consensus 24c... Harley-Davidson (HOG), consensus 34c... Stanley Black & Decker (SWK), consensus $1.52... L-3 Communications (LLL), consensus $2.27... JetBlue (JBLU), consensus 24c.
11:34 EDTABTEC clears Abbott sale of non-U.S. EPD-DM business to Mylan, with conditions
The European Commission has cleared under the EU Merger Regulation the proposed acquisition of Abbott Laboratories' (ABT) Non-U.S. Developed Markets Specialty and Branded Generics Business, or EPD-DM, by Mylan (MYL). The decision is conditional upon the divestment of a number of Mylan's businesses in Germany, the United Kingdom, France, Ireland and Italy. The Commission had concerns that the transaction, as initially notified, would have reduced competition on the market for several medicines. The commitments offered by Mylan address these concerns, the EC said.
January 27, 2015
11:29 EDTBAYRYBayer, Janssen form collaboration to study Xarelto in stroke patients
Subscribe for More Information
09:35 EDTAUXLAuxilium shareholders approve merger with Endo
Subscribe for More Information
January 26, 2015
12:39 EDTCYH, UHSHHS Secretary orders Medicare to change payment method, WSJ says
Subscribe for More Information
07:29 EDTANACAnacor price target raised to $41 from $34 at Jefferies
Subscribe for More Information
07:05 EDTCAHNovaBay signs Avenova distribution agreement with Cardinal Health
Subscribe for More Information
January 23, 2015
08:08 EDTCYHCommunity Health reports agreement for purchase of interest in Metro Health
Subscribe for More Information
January 22, 2015
14:03 EDTAUXLAuxilium to host special shareholder meeting
Subscribe for More Information
07:43 EDTBLUEbluebird bio reinstated with a Buy at BofA/Merrill
Subscribe for More Information
January 21, 2015
12:27 EDTBLUEbluebird bio price target raised to $146 from $94 at Wedbush
Subscribe for More Information
January 20, 2015
13:21 EDTBLUECAR T-Cell therapy drug stocks down sharply following NY Times story
Shares of biotechnology companies that are developing chimeric antigen receptor T cells or CAR T therapy drugs are falling sharply after a New York Times story titled "Riding High, Biotech Firms Remain Wary." WHAT'S NEW: Over the weekend, the New York Times published the story that struck a cautionary tone on the CAR-T therapy drugs. In this form of cancer treatment the patients own immune system cells are genetically manipulated to battle tumors. The New York Times story noted that there were some notable outcomes in the treatment of leukemia and lymphoma with the CAR T treatments but highlighted that the "technique is still early in development and can cause severe side effects." WHAT'S NOTABLE. Early last week, Intrexon (XON) and its oncology partner, ZIOPHARM Oncology (ZIOP), announced an exclusive licensing agreement with The University of Texas MD Anderson Cancer Center, including an exclusive sub-licensing agreement through MD Anderson for intellectual property developed at the University of Minnesota for the development of non-viral adoptive cellular cancer immunotherapies. Both companies' shares were up sharply following the announcement ZIOPHARM was up around 55% and Intrexon up over 30% the day following the announcement. PRICE ACTION: Shares of drug companies in the space are sharply lower in midday trading, with ZIOPHARM Oncology and Kite Pharma (KITE) each down over 9%, Intrexon down almost 12%, and Bellicum Pharmaceutical (BLCM) and bluebird bio (BLUE) each down almost 5%. Reference Link
07:18 EDTCYHCommunity Health sees Q4 EPS $1.23, consensus $1.20
Sees Q4 net operating revenue approx. $4.9B, consensus $5.06B. Excluding acquisition and integration expenses from the acquisition of Hospital Management Associates, legal expenses related to the HMA legal proceedings underlying the CVR agreement, and expenses related to other government legal settlements, adjusted EBITDA is expected to be approximately $785M for the three months ended December 31, 2014.
07:18 EDTCYHCommunity Health Sees FY14 EPS $3.29, consensus $3.21
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use